Drugs / Flublok Quadrivalent
Flublok Quadrivalent
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06015282 Comparator | Nov 2023 → Mar 2024 | influenza | Seqirus | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-18 | Sanofi | European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flublok Quadrivalent | “Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended...” NCT06015282 ↗ |
| Known as | QIVr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015282 ↗ |
| Known as | Supemtek | “Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended...” NCT06015282 ↗ |
| Modality | Vaccine | “Recombinant Quadrivalent Influenza Vaccine” NCT06015282 ↗ |